Rhumbline Advisers Decreases Stake in LeMaitre Vascular, Inc. $LMAT

Key Points

• Rhumbline Advisers has reduced its stake in LeMaitre Vascular, Inc. by 4.7%, now owning 72,123 shares worth approximately $6.05 million after selling 3,538 shares in the first quarter.
• Multiple institutional investors have increased their holdings, with Millennium Management LLC boosting its stake by 119.8% and acquiring an additional 115,141 shares.
• LeMaitre Vascular reported earnings per share of $0.60 for the quarter, above analysts’ expectations, and announced a quarterly dividend of $0.20 per share with a yield of 0.9%.

Rhumbline Advisers reduced its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 4.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 72,123 shares of the medical instruments supplier's stock after selling 3,538 shares during the period. Rhumbline Advisers owned about 0.32% of LeMaitre Vascular worth $6,051,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of LMAT. Millennium Management LLC increased its stake in LeMaitre Vascular by 119.8% in the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier's stock worth $17,722,000 after purchasing an additional 115,141 shares during the period. Invesco Ltd. grew its position in shares of LeMaitre Vascular by 34.5% in the 1st quarter. Invesco Ltd. now owns 235,436 shares of the medical instruments supplier's stock worth $19,753,000 after buying an additional 60,438 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of LeMaitre Vascular by 27.0% during the first quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier's stock valued at $22,019,000 after buying an additional 55,804 shares during the period. Nuveen LLC purchased a new position in shares of LeMaitre Vascular during the first quarter valued at approximately $4,631,000. Finally, Aptus Capital Advisors LLC purchased a new position in shares of LeMaitre Vascular during the first quarter valued at approximately $4,483,000. 84.64% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 2,500 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $94.00, for a total value of $235,000.00. Following the sale, the director directly owned 2,916 shares of the company's stock, valued at approximately $274,104. The trade was a 46.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David B. Roberts sold 10,815 shares of the business's stock in a transaction on Monday, August 11th. The stock was sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director directly owned 17,976 shares in the company, valued at $1,660,802.64. This trade represents a 37.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 120,815 shares of company stock valued at $11,280,206. 9.50% of the stock is owned by insiders.

LeMaitre Vascular Stock Up 0.5%

Shares of NASDAQ LMAT traded up $0.43 during mid-day trading on Thursday, hitting $92.54. 63,127 shares of the stock traded hands, compared to its average volume of 186,930. The company has a debt-to-equity ratio of 0.46, a quick ratio of 11.74 and a current ratio of 13.96. LeMaitre Vascular, Inc. has a 52 week low of $71.42 and a 52 week high of $109.58. The company has a market cap of $2.09 billion, a price-to-earnings ratio of 44.91, a PEG ratio of 2.38 and a beta of 0.79. The stock has a fifty day moving average price of $90.20 and a 200-day moving average price of $85.94.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%.The company had revenue of $63.15 million for the quarter, compared to analyst estimates of $62.48 million. During the same period in the previous year, the company posted $0.52 earnings per share. The firm's revenue was up 15.0% on a year-over-year basis. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. Research analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 4th. Shareholders of record on Thursday, August 21st were issued a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Thursday, August 21st. LeMaitre Vascular's payout ratio is 38.83%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Barrington Research raised LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 target price on the stock in a research note on Wednesday, August 6th. Cantor Fitzgerald boosted their target price on LeMaitre Vascular from $92.00 to $95.00 and gave the company a "neutral" rating in a research note on Wednesday, August 6th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $97.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.